Danaher (NYSE:DHR) Given New $275.00 Price Target at JPMorgan Chase & Co.

Danaher (NYSE:DHR) had its price target upped by JPMorgan Chase & Co. from $270.00 to $275.00 in a research note published on Thursday,Benzinga reports. They currently have an overweight rating on the conglomerate’s stock.

Several other equities analysts have also commented on DHR. Argus set a $265.00 price target on Danaher in a research report on Wednesday, January 14th. Evercore ISI reaffirmed an “outperform” rating and set a $254.00 price target on shares of Danaher in a report on Wednesday. HSBC boosted their price objective on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, December 1st. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research report on Monday, December 29th. Twenty equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $252.55.

Danaher Stock Performance

NYSE:DHR opened at $219.62 on Thursday. The firm’s fifty day simple moving average is $230.77 and its 200 day simple moving average is $213.81. The company has a current ratio of 1.87, a quick ratio of 1.10 and a debt-to-equity ratio of 0.35. Danaher has a twelve month low of $171.00 and a twelve month high of $242.80. The firm has a market capitalization of $155.13 billion, a price-to-earnings ratio of 43.58, a PEG ratio of 3.42 and a beta of 0.89.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.14 by $0.09. The firm had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.14 EPS. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. As a group, equities research analysts expect that Danaher will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is 26.39%.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares in the company, valued at $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Teri List sold 3,298 shares of Danaher stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. The trade was a 13.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 30,248 shares of company stock valued at $6,609,663 over the last three months. 11.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Sivia Capital Partners LLC lifted its holdings in shares of Danaher by 6.3% in the 2nd quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock worth $397,000 after purchasing an additional 119 shares during the last quarter. Capital Investment Advisors LLC boosted its holdings in shares of Danaher by 1.2% during the second quarter. Capital Investment Advisors LLC now owns 7,352 shares of the conglomerate’s stock valued at $1,452,000 after acquiring an additional 85 shares during the period. PFG Investments LLC grew its position in shares of Danaher by 4.6% during the second quarter. PFG Investments LLC now owns 5,233 shares of the conglomerate’s stock worth $1,034,000 after acquiring an additional 228 shares during the last quarter. Childress Capital Advisors LLC increased its holdings in shares of Danaher by 10.6% in the 2nd quarter. Childress Capital Advisors LLC now owns 1,797 shares of the conglomerate’s stock worth $355,000 after acquiring an additional 172 shares during the period. Finally, Community Financial Services Group LLC boosted its stake in Danaher by 5.2% during the 2nd quarter. Community Financial Services Group LLC now owns 19,371 shares of the conglomerate’s stock valued at $3,827,000 after purchasing an additional 960 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

More Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher beat Q4 consensus — reported $2.23 EPS vs. ~$2.14 expected and revenue $6.84B topping estimates, showing growth across Life Sciences, Diagnostics and Bioprocessing. PR Newswire: Q4 Results
• Positive Sentiment: Analyst support: JPMorgan raised its price target to $275 and kept an Overweight rating, highlighting upside vs. current levels and supporting longer‑term conviction. Benzinga: JPMorgan PT Raise
• Neutral Sentiment: FY‑2026 EPS guidance of $8.35–$8.50 was issued and sits essentially inline with the Street (~$8.42), so the outlook is credible but not a positive catalyst above expectations. Reuters: 2026 Forecast
• Neutral Sentiment: Management highlighted strong free cash flow and balance‑sheet strength, which supports buybacks/dividends and long‑term investment in bioprocessing but is not a near‑term growth surprise. TipRanks: Cash Strength
• Negative Sentiment: Market reaction: shares fell after the print as investors parsed the in‑line guidance and cautious commentary on end‑market recovery, leading to short‑term selling despite the beat. Seeking Alpha: Stock Drops
• Negative Sentiment: Commentary emphasized a gradual (not rapid) recovery in pharma spending and continued weakness in some academic research markets — investors looking for a stronger acceleration may have reduced exposure. Benzinga: Gradual Improvement

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.